Sign in
Taking peoplePhase 2

Capsaicin skin patch for painful nerve damage caused by diabetes

Tests capsaicin skin patches in people with painful diabetic neuropathy.

Key facts

Who runs it
Deutsche Diabetes Forschungsgesellschaft e.V.
Where
Germany2 sites in 1 countryChoose a country to see its sites
Registry title
A randomized, double-blind, placebo-controlled study to assess the effects of high concentration capsaicin patch (Qutenza) on neuropathic symptoms, nerve fibers, and microcirculation in painful diabetic peripheral neuropathy
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
29 Jul 2026
Expected to end
31 Mar 2028
Type of study
Interventional
Record updated
20 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with diabetes who have painful nerve damage in the feet or legs. It tests a capsaicin 8% skin patch (Qutenza) against a dummy patch.

Age
18-80 years
Sex
All sexes can join.
Disease stage
Diabetes for ≥1 year. Painful diabetic nerve damage (DSPN) for ≥6 months. Foot or ankle pain of ≥4 points on the NPRS pain scale, but an average daily pain below 9 points. Tingling or abnormal feelings in the legs for ≥6 months. Signs of nerve damage in the legs on exam or tests.
Earlier treatment
Glucose-lowering and pain treatment must be stable for 4 weeks before screening and stay unchanged during the trial. No Capsaicin 179 mg/8% patch in the last 6 months. No other pain treatment put on the painful skin areas in the last 3 months. No more than two pain medicines, no medium or high potency opioids and no electrical stimulation in the last 3 months.
Biomarker or test result
HbA1c <10% (86 mmol/mol) at screening. Skin nerve fiber density of at least 1 fiber/mm in a skin sample. Negative urine pregnancy test for women who could become pregnant.

Main reasons for not taking part

  • Pregnant or breastfeeding women.
  • Foot ulcers in the last 6 months, or amputation of part of the leg.
  • Pain from other causes that cannot be told apart from the diabetic nerve pain.
  • Blood thinners (coumarins or heparin) at treatment dose, or other reasons a skin sample cannot be taken.
  • Cancer in the last 12 months (except basal cell skin cancer or low-grade prostate cancer), alcohol or drug use problems, or uncontrolled high blood pressure.

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Written informed consent signed and dated
  • Willingness to maintain current analgesic treatment unchanged during the course of the study
  • Ability and willingness to meet the study center visits and to undergo study procedures during the whole study duration
  • If applicable, willingness to take acceptable contraceptive measures by female participants in childbearing potential during the treatment phase
  • If applicable, negative urine pregnancy test by female participants in childbearing potential at screening
  • Diabetes mellitus according to the American Diabetes Association criteria (2017), lasting ≥1 year
  • Age: 18-80 years
  • Presence of painful diabetic sensorimotor polyneuropathy (DSPN) as judged by the investigator lasting ≥6 months
  • Presence of pain in the feet and/or ankle caused by painful DSPN as diagnosed by the investigator with an average or maximum NPRS of ≥4 points within 7 days before screening
  • Presence of dysesthesia or paresthesia in the lower extremity caused by DSPN as diagnosed by the investigator lasting ≥6 months
  • Presence of either i) neuropathic deficits in the lower extremity (reduced or absent achilles tendon reflexes, vibration sensation, temperature detection, pain perception, pressure sensation), ii) ≥1 abnormal nerve conduction study parameter in lower extremity peripheral nerves (reduced or not evoked peroneal or tibial motor nerve conduction velocity or sural sensory nerve conduction velocity or amplitude), iii) ≥1 abnormal quantitative sensory test at the lower extremity (temperature detection threshold, vibration perception threshold), or iv) reduced intraepidermal nerve fiber density at screening
  • HbA1c <10% at screening
  • If applicable, stable regimen of glucose-lowering and analgesic treatment for DSPN within 4 weeks prior to screening as judged by the investigator

Who cannot take part

  • Treatment with coumarins or heparin in a therapeutic dose or other contraindications against obtaining skin biopsies at the distal calf
  • Participation in another clinical trial study within the last 3 months prior to screening
  • Neoplasms, except for basal cell carcinoma (basalioma) or low-grade prostate cancer within 12 months prior to screening
  • History of foot ulcers within the last 6 months prior to screening
  • Treatment with Capsaicin 179 mg/8% patch within the last 6 months prior to screening or with any other topical analgesic pain treatment on the areas affected by neuropathic pain due to painful DSPN within the last 3 months prior to screening
  • Concomitant analgesic treatment for painful DSPN with more than two substances, with medium or high potency opioids, or with electrical stimulation within the last 3 months prior to screening
  • Average daily pain level ≥9 points NPRS within 7 days before screening
  • Presence of pain caused by other conditions not clearly differentiated from pDPN as judged by the investigator
  • Currently active or history of alcohol use disorder (>24 units of alcohol per week) or other substance-use disorders as judged by the investigator within the last 5 years
  • Uncontrolled high blood pressure (DBP >95 mmHg and/or SBP >160 mmHg), unless clearly documented to be white-coat hypertension, at screening
  • Mental, psychiatric or other conditions compromising data collection or understanding of written or oral instructions during the study
  • Conditions that might interfere with the assessment of pDPN as judged by the investigator
  • History of amputations at the lower extremity excluding minor amputations due to traumatic events not related to diabetic foot syndrome
  • Contraindications, known allergy, or hypersensitivity to capsaicin or other ingredients of the study medication or local anesthetics
  • Intraepidermal nerve fiber density at screening <1 fiber/mm
  • Pregnant women or nursing mothers
  • Severe resting tachycardia (HR >110 bpm) at screening
  • Substantial change in analgesic treatment regimen during the study as judged by the investigator

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the efficacy of repeated treatment with capsaicin 8% cutaneous patch compared to placebo on skin innervation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A randomized, double-blind, placebo-controlled study to assess the effects of high concentration capsaicin patch (Qutenza) on neuropathic symptoms, nerve fibers, and microcirculation in painful diabetic peripheral neuropathy
Plain-language title
Capsaicin skin patch for painful nerve damage caused by diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
20 January 2026